Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152067 | 0.92 | POLB (0.47) | POLBALDH1A1RECQLSMN1; SMN2MAPT | |
| SCHEMBL24974601 | 0.86 | ROCK2 (0.54) | POLBALDH1A1MAPT | |
| SCHEMBL24974782 | 0.86 | MAPT (0.58) | POLBALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL24974742 | 0.86 | MAPT (0.58) | POLBALDH1A1MAPT | |
| SCHEMBL24974541 | 0.85 | ALDH1A1 (0.52) | POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL24974637 | 0.84 | KMT2A (0.48) | POLBALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL24974592 | 0.83 | ALDH1A1 (0.46) | POLBALDH1A1RECQLSMN1; SMN2DRD2 | |
| SCHEMBL24974633 | 0.77 | PKM (0.47) | POLB | |
| SCHEMBL28751764 | 0.77 | ALDH1A1 (0.74) | POLBALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL24974737 | 0.77 | HDAC1 (0.42) | POLBALDH1A1DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | POLB 4058/4885ALDH1A1 1203/4885RECQL 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.